2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

News

Bolder BioTechnology Announces Publication of Preclinical Studies of BBT-059, a Long-Acting IL-11 Analog, in Mouse Models of the Hematopoietic Acute Radiation Syndrome

Boulder, Colorado – September 5, 2018 – Bolder BioTechnology, Inc. announced today publication of preclinical studies of BBT-059, a long-acting interleukin -11 (IL-11) analog, in mouse models of the hematopoietic acute radiation syndrome. The studies were performed in collaboration with researchers at the Armed Forces Radiobiology Research Institute (AFRRI), the Uniformed Services University of the…
Read more

Bolder BioTechnology Announces Presentation at the 2018 Military Health System Research Symposium

Boulder, Colorado - August 24, 2018  – Bolder BioTechnology is pleased to announce that Dr. Sanchita P. Ghosh of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, was selected to give an oral presentation on preclinical studies of BBT-059, Bolder BioTechnology’s long-acting interleukin-11 analog, at the Military Health…
Read more

Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers

Boulder, Colorado – April 27, 2018- Bolder BioTechnology, Inc. announced today that it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy human volunteers. BBT-015 is being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for Acute Radiation Syndrome. Demonstration that the…
Read more

Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome

BOULDER, Colo., Aug. 2, 2017 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has commenced dosing of patients in a Phase 1 clinical trial of its proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, BBT-015. The trial is designed to study the pharmacokinetics, pharmacodynamics, safety and tolerability of single subcutaneous doses of BBT-015 in healthy human subjects. BBT-015 is…
Read more